Repare Therapeutics Inc. (NASDAQ: RPTX), a clinical-stage precision oncology company, has announced it will present initial topline data from the Phase 1 LIONS (NCT06232408) clinical trial at the forthcoming 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This highly anticipated event is scheduled to take place from October 22 to 26, 2025, in Boston, Massachusetts.The LIONS trial aims to evaluate the safety, tolerability, and early efficacy of novel therapeutic approaches in patients with specific cancer indications. Repare Therapeutics is committed to advancing precision medicine through the development of innovative therapeutics that target the unique genetic and ...
The rapidly evolving field of precision oncology is set to witness another significant leap forward as Repare Therapeutics Inc. (Nasdaq: RPTX) prepares to unveil a suite of new research findings at the American Association for Cancer Research (AACR) Annual Meeting 2025. This year, six groundbreaking abstracts from Repare have been accepted for presentation, showcasing the company s continued leadership and innovation in the fight against cancer.Nestled in the biotech hubs of Cambridge, Massachusetts, and Montreal, Repare Therapeutics is carving a niche for itself as a formidable contender in the clinical-stage precision oncology space. The company stands out for its dedicated efforts to develop targeted canc...
CAMBRIDGE, Mass. and MONTREAL Repare Therapeutics Inc. (Nasdaq: RPTX), a leading clinical-stage precision oncology company, continues to make significant strides in the realm of targeted cancer therapies. The company recently announced three critical updates that highlight its commitment to advancing innovative treatments and its strong clinical capabilities. First Patient Dosed in Camonsertib Monotherapy for NSCLC Expansion On a pivotal note, Repare Therapeutics has dosed the first patient in the expansion phase of their TRESR clinical trial, focusing on the use of camonsertib as a monotherapy for non-small cell lung cancer (NSCLC). This expansion emphasizes the company s robust efforts in targeting ATM...
By Author Name CAMBRIDGE, Mass. and MONTREAL October 12, 2023 Repare Therapeutics Inc., a front-runner in the field of precision oncology, has achieved significant milestones that promise to revolutionize the treatment landscape of hard-to-treat cancers. The U.S. Food and Drug Administration (FDA) has awarded Fast Track designation to lunresertib, in combination with camonsertib, for the treatment of adult patients with CCNE1-amplified, or FBXW7 or PPP2R1A-mutated platinum-resistant ovarian cancer. Concurrently, Repare has dosed its first patient in the Phase 1/1b MYTHIC trial for a novel combination therapy with Debiopharm. FDA Fast Track Designation: A Leap Forward in Ovarian Cancer TreatmentThe Fast Tr...
Sources:
Repare Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Repare Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Repare Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
